John Walter Hanna, Jr. Sells 10,156 Shares of CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. (NASDAQ:CDNA) CEO John Walter Hanna, Jr. sold 10,156 shares of CareDx stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $21.05, for a total transaction of $213,783.80. Following the transaction, the chief executive officer owned 616,885 shares in the company, valued at approximately $12,985,429.25. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

CareDx Stock Up 3.1%

NASDAQ:CDNA opened at $20.83 on Thursday. The business’s 50-day simple moving average is $18.73 and its two-hundred day simple moving average is $15.88. The stock has a market cap of $1.07 billion, a PE ratio of 17.50 and a beta of 2.49. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $25.55.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.15. The firm had revenue of $100.06 million during the quarter, compared to analyst estimates of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The business’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.14) earnings per share. Sell-side analysts anticipate that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Institutional Trading of CareDx

Several hedge funds have recently made changes to their positions in the business. Deerfield Management Company L.P. bought a new position in shares of CareDx in the 3rd quarter valued at about $31,857,000. Braidwell LP bought a new stake in shares of CareDx in the 3rd quarter valued at approximately $31,738,000. Next Century Growth Investors LLC boosted its holdings in shares of CareDx by 309.4% in the 2nd quarter. Next Century Growth Investors LLC now owns 1,125,454 shares of the company’s stock worth $21,991,000 after purchasing an additional 850,580 shares during the period. Bamco Inc. NY increased its position in shares of CareDx by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock valued at $45,876,000 after purchasing an additional 719,523 shares during the last quarter. Finally, Amova Asset Management Americas Inc. increased its position in shares of CareDx by 40.8% during the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,740,064 shares of the company’s stock valued at $25,283,000 after purchasing an additional 504,473 shares during the last quarter.

Wall Street Analyst Weigh In

CDNA has been the subject of a number of research reports. Wall Street Zen upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. BTIG Research increased their price objective on shares of CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Finally, Craig Hallum cut CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target for the company. in a report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $26.67.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.